Merck, 71177-3, Rosetta-gami B Competent Cell Set - Novagen

General description
Genotypes:

Rosetta-gami B

F–ompT hsdSB (rB– mB–) gal dcm lacY1 ahpC gor522::Tn10 trxB pRARE (CamR, KanR, TetR)

Rosetta-gami B(DE3)

F–ompT hsdSB (rB– mB–) gal dcm lacY1 ahpC (DE3) gor522::Tn10 trxB pRARE (CamR, KanR, TetR)

Rosetta-gami B(DE3)pLysS

F–ompT hsdSB (rB– mB–) gal dcm lacY1 ahpC (DE3) gor522::Tn10 trxB pLysSRARE (CamR, KanR, TetR)

This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges us to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.
Rosetta-gami B strains combine the key features of BL21 (and its Tuner derivative), Origami, and Rosetta to enhance both the expression of eukaryotic proteins and the formation of target protein disulfide bonds in the bacterial cytoplasm. These strains are compatible with ampicillin- or spectinomycin-resistant vectors.

DE3 indicates that the host is a lysogen of λDE3, and therefore carries a chromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter. Such strains are suitable for production of protein from target genes cloned in pET vectors by induction with IPTG.

pLysS strains express T7 lysozyme, which further suppresses basal expression of T7 RNA polymerase prior to induction, thus stabilizing pET recombinants encoding target proteins that affect cell growth and viability.
Other Notes
•2 × 0.2 mlRosetta-gami B Competent Cells

•2 × 0.2 mlRosetta-gami B(DE3) Competent Cells

•2 × 0.2 mlRosetta-gami B(DE3)pLysS Competent Cells

•4 × 2 mlSOC Medium

•2 ngTest Plasmid

Legal Information
NOVAGEN is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Multiple Toxicity Values, refer to MSDS (O)